| References: |
AMI-1 is a potent, cell-permeable compound which inhibits protein arginine N-methyltransferases (PRMTs), including human PRMT1 (IC50 = 8.8μM) and yeast-Hmt1p (IC50 = 3.0μM), by blocking peptide-substrate binding. AMI-1 does not compete for the AdoMet (S-adenosyl-L-methionine; SAM) binding site and exhibits minimal effects on both SET (Sub39H1, Suv39H2, SET7) and non-SET (DOT1) lysine N-methyltransferases. AMI-1 suppresses the transcriptional coactivator activity of PRMT1 and PRMT4 and it inhibits HIV-1 RT polymerase (IC50 = 5.0μM). PRMT1 methylates histone H4, and is essential for other subsequent histone modifications. For the detailed information of AMI-1, the solubility of AMI-1 in water, the solubility of AMI-1 in DMSO, the solubility of AMI-1 in PBS buffer, the animal experiment (test) of AMI-1, the cell expriment (test) of AMI-1, the in vivo, in vitro and clinical trial test of AMI-1, the EC50, IC50,and affinity,of AMI-1, For the detailed information of AMI-1, the solubility of AMI-1 in water, the solubility of AMI-1 in DMSO, the solubility of AMI-1 in PBS buffer, the animal experiment (test) of AMI-1, the cell expriment (test) of AMI-1, the in vivo, in vitro and clinical trial test of AMI-1, the EC50, IC50,and affinity,of AMI-1, Please contact DC Chemicals. |
